SG11202111084WA - Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof - Google Patents
Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereofInfo
- Publication number
- SG11202111084WA SG11202111084WA SG11202111084WA SG11202111084WA SG11202111084WA SG 11202111084W A SG11202111084W A SG 11202111084WA SG 11202111084W A SG11202111084W A SG 11202111084WA SG 11202111084W A SG11202111084W A SG 11202111084WA SG 11202111084W A SG11202111084W A SG 11202111084WA
- Authority
- SG
- Singapore
- Prior art keywords
- vitamins
- pyrimidine
- preparation
- dosage forms
- solid dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382340 | 2019-05-06 | ||
| PCT/EP2019/080413 WO2020224795A1 (en) | 2019-05-06 | 2019-11-06 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111084WA true SG11202111084WA (en) | 2021-11-29 |
Family
ID=66529933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111084WA SG11202111084WA (en) | 2019-05-06 | 2019-11-06 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220160744A1 (en) |
| EP (1) | EP3965744A1 (en) |
| JP (1) | JP2022531663A (en) |
| KR (1) | KR20220005024A (en) |
| CN (1) | CN113784706B (en) |
| AU (1) | AU2019444412A1 (en) |
| BR (1) | BR112021021769A2 (en) |
| CA (1) | CA3137221A1 (en) |
| CL (1) | CL2021002874A1 (en) |
| CO (1) | CO2021015353A2 (en) |
| DO (1) | DOP2021000225A (en) |
| EA (1) | EA202193041A1 (en) |
| EC (1) | ECSP21080548A (en) |
| JO (1) | JOP20210296A1 (en) |
| MA (1) | MA55857A (en) |
| MX (1) | MX2021013565A (en) |
| PE (1) | PE20220498A1 (en) |
| SG (1) | SG11202111084WA (en) |
| TW (1) | TWI827736B (en) |
| UA (1) | UA127913C2 (en) |
| WO (1) | WO2020224795A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA995133A (en) * | 1973-03-29 | 1976-08-17 | Shunkichi Tamura | Uridine-5'-monophosphate compositions |
| GB1363398A (en) * | 1973-03-29 | 1974-08-14 | Yamasa Shoyu Kk | Uridine-5.-monophosphate compositions |
| JPH01308232A (en) * | 1988-06-03 | 1989-12-12 | Takeda Chem Ind Ltd | Solid drug and production thereof |
| DE10215753A1 (en) * | 2002-04-10 | 2003-10-30 | Trommsdorff Arzneimittel | Use of pyrimidine nucleotides for the treatment of damage to the peripheral nervous system |
| CN101184496A (en) * | 2005-05-27 | 2008-05-21 | 兴和株式会社 | Pharmaceutical preparation for recovery from fatigue |
| KR100869444B1 (en) * | 2007-07-11 | 2008-11-18 | 주식회사 중외제약 | Multi-layered vitamin complex tablet containing ubidecarenone |
| WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| EP3366291A1 (en) * | 2017-02-22 | 2018-08-29 | Montero Gida Sanayi Ve Ticaret A.S. | Solid oral pharmaceutical compositions comprising alpha lipoic acid and water-soluble vitamins |
-
2019
- 2019-11-06 EP EP19805905.7A patent/EP3965744A1/en active Pending
- 2019-11-06 EA EA202193041A patent/EA202193041A1/en unknown
- 2019-11-06 AU AU2019444412A patent/AU2019444412A1/en active Pending
- 2019-11-06 BR BR112021021769A patent/BR112021021769A2/en unknown
- 2019-11-06 JP JP2021564927A patent/JP2022531663A/en active Pending
- 2019-11-06 CN CN201980096023.8A patent/CN113784706B/en active Active
- 2019-11-06 MA MA055857A patent/MA55857A/en unknown
- 2019-11-06 CA CA3137221A patent/CA3137221A1/en active Pending
- 2019-11-06 KR KR1020217037742A patent/KR20220005024A/en unknown
- 2019-11-06 UA UAA202106780A patent/UA127913C2/en unknown
- 2019-11-06 US US17/606,701 patent/US20220160744A1/en active Pending
- 2019-11-06 WO PCT/EP2019/080413 patent/WO2020224795A1/en active Search and Examination
- 2019-11-06 PE PE2021001823A patent/PE20220498A1/en unknown
- 2019-11-06 JO JOP/2021/0296A patent/JOP20210296A1/en unknown
- 2019-11-06 SG SG11202111084WA patent/SG11202111084WA/en unknown
- 2019-11-06 MX MX2021013565A patent/MX2021013565A/en unknown
- 2019-11-22 TW TW108142537A patent/TWI827736B/en active
-
2021
- 2021-11-01 DO DO2021000225A patent/DOP2021000225A/en unknown
- 2021-11-02 CL CL2021002874A patent/CL2021002874A1/en unknown
- 2021-11-15 EC ECSENADI202180548A patent/ECSP21080548A/en unknown
- 2021-11-16 CO CONC2021/0015353A patent/CO2021015353A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2021000225A (en) | 2022-03-15 |
| EP3965744A1 (en) | 2022-03-16 |
| AU2019444412A1 (en) | 2021-11-04 |
| CA3137221A1 (en) | 2020-11-12 |
| CN113784706B (en) | 2024-01-05 |
| WO2020224795A1 (en) | 2020-11-12 |
| MA55857A (en) | 2022-03-16 |
| EA202193041A1 (en) | 2022-02-10 |
| BR112021021769A2 (en) | 2021-12-28 |
| UA127913C2 (en) | 2024-02-07 |
| PE20220498A1 (en) | 2022-04-07 |
| ECSP21080548A (en) | 2022-02-25 |
| KR20220005024A (en) | 2022-01-12 |
| CO2021015353A2 (en) | 2021-11-19 |
| JP2022531663A (en) | 2022-07-08 |
| JOP20210296A1 (en) | 2023-01-30 |
| MX2021013565A (en) | 2022-01-04 |
| CL2021002874A1 (en) | 2022-06-17 |
| TWI827736B (en) | 2024-01-01 |
| US20220160744A1 (en) | 2022-05-26 |
| TW202108132A (en) | 2021-03-01 |
| CN113784706A (en) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4233846A3 (en) | Pharmaceutical formulations | |
| MX2017016802A (en) | Pharmaceutical formulations. | |
| EP3481831A4 (en) | NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| IL270812B1 (en) | Solid compositions for oral administration comprising semaglutide and dapagliflozin and their use in medicine | |
| IL283455A (en) | Pill dispenser for medications, vitamins and/or dietary supplements | |
| GB201620066D0 (en) | Solid Pharmaceutical dosage formulations and processes | |
| IL256610B (en) | Pyrimidine derivatives, their preparation and pharmaceutical compositions containing them | |
| EP3873442A4 (en) | Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans | |
| IL272638A (en) | Quinoxaline derivatives, their preparation and pharmaceutical compositions containing them | |
| EP3400964A4 (en) | Taste-masked and orally administered pharmaceutical preparation containing varenicline or pharmaceutically acceptable salt thereof | |
| IL248095A0 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir | |
| IL210544A (en) | Pharmaceutical compositions comprising pyrazole derivatives, orally bioavailable solid dosage forms comprising them and uses thereof in the preparation of medicaments | |
| IL280083A (en) | Pharmaceutical dosage form which can be administered orally and has modified release | |
| IL285421A (en) | Indazolyl-isoxazole derivatives, their preparation and pharmaceutical compositions containing them | |
| HK1220390A1 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
| SG11202111084WA (en) | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | |
| IL273240A (en) | Oral-surface administered preparation for the prevention of illnesses acquired via the oral cavity and the pharynx | |
| PL3326619T3 (en) | Solid oral pharmaceutical compositions comprising tenofovir and emtricitabine | |
| EP4052699A4 (en) | Orally administered solid dosage form drug | |
| EP4087574A4 (en) | Pyrimidine compounds and their pharmaceutical uses | |
| EP4190310A4 (en) | Stable pharmaceutical preparation | |
| EP4034120A4 (en) | Solid oral pharmaceutical formulations comprising sapropterin dihydrochloride and at least one pharmaceutical excipient | |
| PL3630188T3 (en) | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | |
| WO2014184663A3 (en) | Orally dispersible drug formulations | |
| EP3141264A4 (en) | Pharmaceutical preparation for masked taste oral administration, containing clomipramine |